BioMarin gets first access deal in EU for gene therapy ROCTAVIAN™
BioMarin has signed the first contract with an insurer in Germany for ROCTAVIAN™, its recently approved gene therapy for haemophilia A, as it tests its outcomes-based agreement (OBA) reimbursement model in the EU.
The company’s Chief Executive, Jean-Jacques Bienaimé, explained at the J.P. Morgan Healthcare Conference this week that it expects to sign several more contracts with German insurers in the coming weeks, and has started reimbursement negotiations with the authorities in France and Italy. The first contract is with one of the top three health insurers in Germany that BioMarin estimates collectively represent about 80% of German citizens.
Read the full story here.